Wedge Capital Management’s Pacira BioSciences PCRX Stock Holding History

Wedge Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.4M	Buy	+94,554	New	+$2.23M	0.04%	308
2024 Q4	–	Sell	-119,447	Closed	-$1.8M	–	525
2024 Q3	$1.8M	Buy	119,447 +67,947	+132%	+$1.16M	0.03%	344
2024 Q2	$1.47M	Sell	51,500 -4,883	-9%	-$139K	0.03%	349
2024 Q1	$1.65M	Buy	56,383 +24,969	+79%	+$767K	0.03%	346
2023 Q4	$1.06M	Buy	+31,414	New	+$919K	0.02%	355

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wedge Capital Management's PCRX Position: Q2 2026 in Review

Wedge Capital Management opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 94,554 shares worth $2.4M. The stake represents 0.04% of the portfolio and ranks #308 among its holdings. This is a return to the name: Wedge Capital Management previously reported a position in PCRX as recently as Q3 2024.

Wedge Capital Management first reported a position in PCRX in Q4 2023 and has held it in 5 quarters since. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Wedge Capital Management held 94,554 shares of Pacira BioSciences worth $2.4M as of Q2 2026.
Pacira BioSciences was a new Wedge Capital Management position in Q2 2026.
Pacira BioSciences made up 0.04% of Wedge Capital Management's portfolio in Q2 2026, its #308 holding.
Wedge Capital Management first reported a position in Pacira BioSciences in Q4 2023 and has held it in 5 quarters since.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Wedge Capital Management's 13F filing for Q2 2026, filed 10 Jul 2026.